Thyrotropinomas

Paolo Beck-Peccoz; Luca Persani

doi:10.1016/j.ecl.2007.10.001

Thyrotropinomas

Paolo Beck-Peccoz, Luca Persani

Research output: Contribution to journal › Article › peer-review

Abstract

Thyrotropinomas are easily recognized, owing to the availability of ultrasensitive thyropin immunometric assays. These methods allow a clear distinction between patients who have suppressed and those who have nonsuppressed circulating thyrotropin concentrations. In the latter, it is mandatory to perform a differential diagnosis, as the management of the two disorders is completely different, and failure to recognize the presence of a thyrotropinoma may result in dramatic consequences. Adenomectomy is the firstline treatment of thyrotropinomas, followed by irradiation in the case of surgical failure. Medical treatment with somatostatin analogs is effective in reducing thyrotropin secretion in more than 90% of cases.

Original language	English
Pages (from-to)	123-134
Number of pages	12
Journal	Endocrinology and Metabolism Clinics of North America
Volume	37
Issue number	1
DOIs	https://doi.org/10.1016/j.ecl.2007.10.001
Publication status	Published - Mar 2008

ASJC Scopus subject areas

Endocrinology
Biochemistry

Access to Document

10.1016/j.ecl.2007.10.001

Fingerprint Dive into the research topics of 'Thyrotropinomas'. Together they form a unique fingerprint.

Cite this

@article{6637b1047dca4866bde12a12d7aeba3d,

title = "Thyrotropinomas",

abstract = "Thyrotropinomas are easily recognized, owing to the availability of ultrasensitive thyropin immunometric assays. These methods allow a clear distinction between patients who have suppressed and those who have nonsuppressed circulating thyrotropin concentrations. In the latter, it is mandatory to perform a differential diagnosis, as the management of the two disorders is completely different, and failure to recognize the presence of a thyrotropinoma may result in dramatic consequences. Adenomectomy is the firstline treatment of thyrotropinomas, followed by irradiation in the case of surgical failure. Medical treatment with somatostatin analogs is effective in reducing thyrotropin secretion in more than 90% of cases.",

author = "Paolo Beck-Peccoz and Luca Persani",

year = "2008",

month = mar,

doi = "10.1016/j.ecl.2007.10.001",

language = "English",

volume = "37",

pages = "123--134",

journal = "Endocrinology and Metabolism Clinics of North America",

issn = "0889-8529",

publisher = "W.B. Saunders Ltd",

number = "1",

}

TY - JOUR

T1 - Thyrotropinomas

AU - Beck-Peccoz, Paolo

AU - Persani, Luca

PY - 2008/3

Y1 - 2008/3

N2 - Thyrotropinomas are easily recognized, owing to the availability of ultrasensitive thyropin immunometric assays. These methods allow a clear distinction between patients who have suppressed and those who have nonsuppressed circulating thyrotropin concentrations. In the latter, it is mandatory to perform a differential diagnosis, as the management of the two disorders is completely different, and failure to recognize the presence of a thyrotropinoma may result in dramatic consequences. Adenomectomy is the firstline treatment of thyrotropinomas, followed by irradiation in the case of surgical failure. Medical treatment with somatostatin analogs is effective in reducing thyrotropin secretion in more than 90% of cases.

AB - Thyrotropinomas are easily recognized, owing to the availability of ultrasensitive thyropin immunometric assays. These methods allow a clear distinction between patients who have suppressed and those who have nonsuppressed circulating thyrotropin concentrations. In the latter, it is mandatory to perform a differential diagnosis, as the management of the two disorders is completely different, and failure to recognize the presence of a thyrotropinoma may result in dramatic consequences. Adenomectomy is the firstline treatment of thyrotropinomas, followed by irradiation in the case of surgical failure. Medical treatment with somatostatin analogs is effective in reducing thyrotropin secretion in more than 90% of cases.

UR - http://www.scopus.com/inward/record.url?scp=38349156151&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38349156151&partnerID=8YFLogxK

U2 - 10.1016/j.ecl.2007.10.001

DO - 10.1016/j.ecl.2007.10.001

M3 - Article

C2 - 18226733

AN - SCOPUS:38349156151

VL - 37

SP - 123

EP - 134

JO - Endocrinology and Metabolism Clinics of North America

JF - Endocrinology and Metabolism Clinics of North America

SN - 0889-8529

IS - 1

ER -